About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

NCT00536692·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

CoMentis

With

Juvenile Diabetes Research Foundation

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

macular edema due to diabetic retinopathy

You may not be if

vision loss from other ocular disease
intraocular surgery within 3 months
intraocular anti-VEGF or steroids within 3 months
HbA1c \>12

The record

StatusCompleted

PhasePhase 2

Taking part—

StartedSep 2007

UpdatedApr 8, 2008

Conditions

Diabetic Macular Edema

Where3

East Bay Retina Consultants, Inc.
Oakland, California, United States
Johns Hopkins School of Medicine / Wilmer Eye Institute
Baltimore, Maryland, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States

Clareo Health | Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)